**Find the Fact Sheet on NTRK/TrkB here:** <http://oncologypro.esmo.org/Publications/Glossary-of-Molecular-Biology/Glossary-in-Molecular-Biology>

Introduction {#s1}
============

The treatment of solid tumours is dramatically changing in recent years thanks to the enhancement of molecular diagnostic technologies leading to identification of an increasing number of specific actionable oncogenic abnormalities such as gene activating point mutations, in-frame insertions/deletions and amplification or rearrangements. The concept of precision medicine consists in the accomplishment of therapy individualised to each tumour by exploiting these alterations as predictive biomarkers as well as targets of therapy. Neurotrophic tropomyosin receptor kinase (*NTRK*) gene rearrangements have recently emerged as targets for cancer therapy, because novel compounds have been developed that are selective inhibitors of the constitutively active fusion proteins that arise from these molecular alterations. Developments in this field are being aided by next generation sequencing methods as tools for unbiased gene fusion discovery. In this article, we review the role of *NTRK* gene fusions across several tumour histologies, and the promises and challenges of targeting such genetic alterations for cancer therapy.

Tropomyosin receptor kinase (Trk) family of receptors {#s1a}
=====================================================

The Trk receptor family comprises three transmembrane proteins referred to as Trk A, B and C (TrkA, TrkB and TrkC) receptors, and are encoded by the *NTRK1*, *NTRK2* and *NTRK3* genes*,* respectively. These receptor tyrosine kinases (TK) are expressed in human neuronal tissue, and play an essential role in both the physiology of development and function of the nervous system through activation by neurotrophins (NTs).[@R1] The latter are specific ligands known as nerve growth factor (NGF) for TrkA, brain-derived growth factor (BDGF), and NT-4/5 for TrkB and NT3 for TrkC, respectively.[@R2] All three Trk receptors are structured with an extracellular domain for ligand binding, a transmembrane region and an intracellular domain with a kinase domain. The binding of the ligand to the receptor triggers the oligomerisation of the receptors and phosphorylation of specific tyrosine residues in the intracytoplasmic kinase domain. This event results into the activation of signal transduction pathways leading to proliferation, differentiation and survival in normal and neoplastic neuronal cells[@R1] ([figure 1](#ESMOOPEN2015000023F1){ref-type="fig"}). The binding of TrkA receptor by NGF causes the activation of the Ras/Mitogen activated protein kinase (MAPK) pathway, which leads to increased proliferation and cellular growth through extracellular signal-regulated kinase (ERK) signalling. Other pathways such as phospholipase C-γ (PLCγ) and PI3K are also activated. TrkC coupling with NT3 causes preferential activation of the PI3/AKT pathway preventing apoptosis and increasing cell survival, whereas TrkB transduces the BDNF signal via Ras-ERK, PI3K and PLCγ pathway, resulting in neuronal differentiation and survival.[@R1] The Trk receptor kinases play a key role in central and peripheral nervous system development as well as in cell survival. The proper regulation of Trk receptor levels and their activation is critically important in cell functioning, and the upregulation of Trk receptors has been reported in several central nervous system-related disorders (eg, TrkB in epilepsy, neuropathic pain, or depression).[@R3]

![Schematic view of Trk receptors signalling, showing the three major pathways involved in cell differentiation and survival. AKT, v-akt murine thymoma viral oncogene homologue; BDGF, brain-derived growth factor; DAG, diacyl-glycerol; ERK, extracellular signal-regulated kinase; GAB1, GRB2-associated-binding protein 1; GRB2, growth factor receptor-bound protein 2; IP3, inositol trisphosphate; MEK, mitogen-activated protein kinase; NGF, nerve growth factor; NTF-3, neurotrophin 3; PI3K, phosphatidylinositol-4,5-bisphosphate 3-kinase; PIP2, phosphatidylinositol 4,5-bisphosphate; PKC, protein kinase C; PLC, phospholipase C; RAF, rapidly accelerated fibrosarcoma kinase; RAS, rat sarcoma kinase; SHC, Src homology 2 domain containing.](esmoopen2015000023f01){#ESMOOPEN2015000023F1}

The *NTRK1* gene is located on chromosome 1q21-q22,[@R4] and its mutations disrupting the function of the TrkA protein are found in patients affected by congenital insensitivity to pain with anhidrosis (CIPA) syndrome.[@R5] In 1999 Indo *et al* cloned the full-length *NTRK1* human gene encoding a 790-residue or 796-residue protein (TrkA receptor) with an intracellular domain containing a juxtamembrane region, a TK domain and a short C terminal tail.[@R6]

The *NTRK2* gene is mapped on chromosome 9q22.1[@R7] and contains 24 exons,[@R8] coding for a protein of 822 amino acid residues (TrkB receptor). The full-length TrkB receptor contains an N-terminal signal sequence, followed by a cysteine-rich domain, a leucine-rich domain, a second cysteine-rich domain, 2 immunoglobulin (Ig)-like domains that make up the BDNF-binding region, a transmembrane domain, a Src homology 2 domain containing (SHC)-binding motif, a TK domain near the C terminus and a C-terminal PLCγ-docking site.

The *NTRK3* gene is located on chromosome 15q25,[@R9] and its transcription product known as TrkC was isolated and characterised by Lamballe *et al*[@R10] in 1991. TrkC receptor is a glycoprotein of 145 kD preferentially expressed in the human hippocampus, cerebral cortex and in the granular cell layer of the cerebellum.

Molecular alterations of *NTRK* genes in various malignancies across histologies {#s1b}
================================================================================

Gene fusions of *NTRK* genes represent the main molecular alterations with known oncogenic and transforming potential.[@R11] Less common oncogenic mechanisms that have been described are in-frame deletion of *NTRK1* in acute myeloid leukaemia[@R12] and a TrkA alternative splicing in neuroblastoma.[@R13] In all reported Trk oncogenic gene fusions, the 3' region of the *NTRK* gene is joined with a 5' sequence of a fusion partner gene by an intrachromosomal or interchromosomal rearrangement, and the oncogenic chimaera is typically a constitutively activated or overexpressed kinase ([figure 2](#ESMOOPEN2015000023F2){ref-type="fig"}). [Table 1](#ESMOOPEN2015000023TB1){ref-type="table"} shows the NTRK fusions reported to date and their associated cancer types.

###### 

Reported gene fusions involving NTRK genes along with the corresponding tumour

  Gene fusion                           Cancer type                                                                                  Authors (year)
  ------------------------------------- -------------------------------------------------------------------------------------------- ---------------------------------------------------------------------
  ***NTRK1***                                                                                                                        
  LMNA-NTRK1                            Colorectal                                                                                   Sartore-Bianchi *et al* (2016)
  Soft tissue sarcoma                   Doebele *et al* (2015)                                                                       
  Spitzoid melanomas                    Wiesner *et al* (2014)                                                                       
  AYA sarcoma                           Morosini *et al* (2015)                                                                      
  Congenital infantile fibrosarcoma     Wong *et al* (2015)                                                                          
  TPM3-NTRK1                            Colorectal                                                                                   Lee *et al* (2015), Créancier *et al* (2015), Ardini *et al* (2014)
  Papillary thyroid carcinomas          Bongarzone *et al* (1989), Butti *et al* (1995)                                              
  Glioblastoma                          Wu *et al* (2014)                                                                            
  SQSTM1-NTRK1                          NSCLC                                                                                        Farago *et al* (2015)
  NTRK1-SQSTM1                          NSCLC                                                                                        Siena *et al* (2015)
  NFASC-NTRK1                           Glioblastoma multiforme                                                                      Frattini *et al* (2013), Kim *et al* (2014)
  BCAN-NTRK1                            Glioblastoma multiforme                                                                      Kim *et al* (2014), Frattini *et al* (2013)
  PPL-NTRK1                             Thyroid carcinoma                                                                            Farago *et al* (2015)
  RFWD2-NTRK1                           Large cell neuroendocrine tumour (lung)                                                      Fernandez-Cuesta *et al* (2014)
  CD74-NTRK1                            Lung adenocarcinomas                                                                         Vaishnavi *et al* (2013)
  MPRIP-NTRK1                           Lung adenocarcinomas                                                                         Vaishnavi *et al* (2013)
  RABGAP1L-NTRK1                        ICC                                                                                          Ross *et al* (2014)
  TFG-NTRK1                             Thyroid carcinomas                                                                           Greco *et al* (1995)
  TP53-NTRK1                            Spitzoid melanomas                                                                           Wiesner *et al* (2014)
  ***NTRK2***                                                                                                                        
  Unknown-NTRK1                         Appendiceal adenocarcinoma                                                                   Braghiroli *et al* (2016)
  AFAP1-NTRK2                           Low-grade glioma                                                                             Stransky *et al* (2014)
  AGBL4-NTRK2                           Glioblastoma                                                                                 Wu *et al* (2014)
  NACC2-NTRK2                           Pilocytic astrocytomas                                                                       Jones *et al* (2013)
  PAN3-NTRK2                            Head and neck squamous cell carcinoma                                                        Wu *et al* (2014)
  QKI-NTRK2                             Pilocytic astrocytomas                                                                       Jones *et al* (2013)
  TRIM24-NTRK2                          Lung adenocarcinoma                                                                          Wu *et al* (2014)
  VCL-NTRK2                             Glioblastoma                                                                                 Wu *et al* (2014)
  ***NTRK3***                                                                                                                        
  ETV6-NTRK3                            Glioblastoma                                                                                 Zhang *et al* (2013)
  Glioblastoma                          Wu *et al* (2014)                                                                            
  MASC                                  Tognon *et al* (2002), Ito *et al* (2015), Del Castillo *et al* (2015)                       
  Ductal carcinoma                      Makretsov *et al* (2004), Arce *et al* (2005), Lagree *et al* (2011), Pinto *et al* (2014)   
  Fibrosarcoma                          Morerio *et al* (2004), Punnett *et al* (2000)                                               
  Congenital mesoblastic nephroma       Watanabe *et al* (2002)                                                                      
  Radiation-associated thyroid cancer   Leeman-Neill *et al* (2014)                                                                  
  AML                                   Kralik *et al* (2011), Eguchi *et al* (1999), Knezevich *et al* (1998)                       
  GIST                                  Brenca *et al* (2015)                                                                        
  MASC of salivary gland                Urano *et al* (2015), Skàlovà *et al* (2015)                                                 
  Papillary thyroid cancer              Leeman-Neill *et al* (2014), Seungbok Lee *et al* (2014)                                     
  Colorectal                            Hechtman *et al* (2015)                                                                      
  BTBD1-NTRK3                           Glioblastoma                                                                                 Wu *et al* (2014)

AFAP1, actin filament-associated protein 1; AGBL4, ATP/GTP-binding protein-like 4; AML, acute myeloid leukaemia; AYA, adolescents and young adults; BCAN, brevican; BTBD1, BTB (POZ) domain containing 1; CD74, CD74 molecule; ETV6, ets variant 6; GIST, gastrointestinal stromal tumor; ICC, intrahepatic cholangiocarcinoma; LMNA, lamin A/C; MASC, mammary secretory breast carcinoma; MPRIP, myosin phosphatase Rho interacting protein; NACC2, NACC family member 2, BEN and BTB (POZ) domain containing; NFASC, neurofascin; NSCLC, non-small cell lung cancer; PAN3, PAN3 poly(A) specific ribonuclease subunit; PPL, periplakin; QKI, KH domain containing RNA binding; RABGAP1L, RAB GTPase activating protein 1-like; RFWD2, ring finger and WD repeat domain 2, E3 ubiquitin protein ligase; SQSTM1, sequestosome 1; TFG, TRK-fused gene; TP53, tumour protein p53; TPM3, tropomyosin 3; TRIM24, tripartite motif containing 24; VCL, vinculin.

![The chimeric Trk protein, composed by the TK domain with ATPase activity and a TM loop along with a fusion partner. Oligomerisation of the chimeric protein is the main proposed mechanisms for increased tumour cell survival and proliferation via the known pathways of Trk receptors. (A) *NTRK1* gene with 17 exon sequences and respective TrkA protein regions.[@R5] (B) Mechanism of entrectinib (E) action and the known mechanisms of acquired resistance (point mutation G595R and G567C) to E.[@R50] Cys, cysteine clusters; Ig1 and Ig2, first and second immunoglobulin-like motifs, respectively; LRM, leucine-rich motifs; SP, signal peptide; TK, tyrosine kinase; TM, transmembrane.](esmoopen2015000023f02){#ESMOOPEN2015000023F2}

*Colorectal adenocarcinoma*: It has been believed for more than three decades since the seminal work of Fearon and Vogelstein[@R14] on molecular carcinogenesis of colorectal carcinoma (CRC), that rearrangement of oncogenes are of such low prevalence, as compared with DNA sequencing alteration or amplifications, that their role is almost negligible in the genesis of this tumour type. The first published report of a *NTRK* rearrangement in CRC dates back to 1986,[@R15] when a *TPM3-NTRK1* translocation was detected in a tumour biopsy, and thereafter very little has been reported about these gene defects in CRC. However, the *NTRK* gene fusions and their oncogenic potential in this tumour as oncogenes may have been underestimated, mostly because of the absence, until recently, of targeted therapies exploiting these gene abnormalities. These circumstances resemble what previously occurred with *ALK* (Anaplastic Lymphoma Kinase) gene fusions in non-small cell lung cancer (NSCLC), in which despite evidence of *ALK* fusions since 2007,[@R16] the scientific interest was raised only after synthesis of compounds with ALK-specific inhibitory activity.[@R17] In particular, in 2014, Ardini *et al* reported the characterisation of the *TPM3-NTRK1* gene rearrangement as a recurring, although rare, event in CRC, and also discovered entrectinib (NMS-P626; RXDX-101) as a novel, highly potent and selective pan-Trk inhibitor. Entrectinib suppressed TPM3-TRKA phosphorylation and downstream signalling in KM12 cells and showed remarkable antitumour activity in mice bearing KM12 tumours. Also, in 2015, Créancier *et al*[@R18] reported the 0.5% prevalence of NTRK fusions in 408 CRC clinical samples, including a TPM3-NTRK1 (TRK-T2 fusion). Recently, in the molecular screening within the phase I first-in-human study of entrectinib (EudraCT number: 2012-000148-88), an abnormal expression of the TrkA protein was identified in tumour and liver metastases of a patient with CRC refractory to standard therapy, and molecular characterisation unveiled a novel *LMNA-NTRK1* rearrangement within chromosome 1, with oncogenic potential. The patient was treated with entrectinib, achieving objective partial response with decrease of metastatic lesions in the liver and adrenal gland.[@R19] Further, as a part of the molecular screening of the Memorial Sloan Kettering IMPACT (MSK-IMPACT) programme,[@R20] Braghiroli *et al*[@R21] reported a 4% (2 of the 49 cases) of incidence of NTRK unidentified fusions in appendiceal adenocarcinoma.

*Lung adenocarcinoma*: Gene rearrangements have already emerged as therapeutic targets in NSCLC,[@R22] since Food and Drug Administration (FDA) and European Medicines Evaluation Agency (EMEA) approval of crizotinib for patients with NSCLC harbouring *EML4-ALK* translocations. In 2013, Vaishnavi *et al*[@R23] described two different gene fusions involving the *NTRK1* gene that lead to constitutive TrkA TK domain activation. The first was characterised by a rearrangement of the 5' portion of the myosin phosphatase Rho-interacting protein (*MPRIP*) gene fused to the 3' portion of *NTRK1*; the resultant protein (RIP-TrkA) encoded by this fusion showed in cultured cells autophosphorylation of the fusion protein at critical tyrosine residues in cultured cells, implying its constitutive activation. The second gene fusion was characterised by a rearrangement between the *CD74* and *NTRK1* gene. In the same study, the authors also reported a *TPM53*-*NTRK1* fusion (similar to that already described in CRC). A total of 3.3% patients in this study (3/91) harboured *NTRK* rearrangements potentially susceptible to TrkA inhibitors. In 2014, Stransky *et al*[@R24] identified a novel *TRIM24-NTRK2* gene fusion in lung adenocarcinoma through an unbiased computational pipeline designed for the identification of gene fusions in the data set from The Cancer Genome Atlas (TCGA).

*Papillary thyroid carcinoma* (*PTC*): A few years after the first published paper of a *NTRK* rearrangement in colorectal cancer, Bongarzone *et al*[@R25] in 1989 described an oncogenic version of *NTRK1* in PTC. Further works showed that oncogenic *NTRK1* rearrangements in PTC are the consequence of the fusion of the TK domain of *NTRK1* oncogene with 5-terminal sequences of at least three different genes. *TRK-T1* and *TRK-T2* are two different hybrid forms derived from chromosome inversion and different portions of TPR (Translocated Promoter Region) gene on chromosome 1q25 activate them. Another *NTRK1* oncogene obtained by fusion with the *TFG* gene (*TRK* fused gene) on chromosome 3 is *TRK--T3*. All these oncogenic forms of *NTRK1* gene encode cytoplasmic hybrid proteins that are constitutively phosphorylated at tyrosine residues.[@R26] Somatic rearrangements of the *NTRK1* gene in PTC usually do not exceed 12%, but range quite widely across different populations (from 15% to 50% in the Italian population[@R27] to \<10% in French,[@R28] Japanese[@R29] and Chinese[@R30]). A rare chromosomal rearrangement in sporadic thyroid cancer, but more frequent in radiation-related tumours, is *ETV6-NTRK3*, which results from an interchromosomal translocation t(12;15)(p13;q25) that juxtaposes exons 1--4 of *ETV6* to exons 12--18 of *NTRK3*. The breakpoint differs from those reported in congenital fibrosarcomas and secretory breast cancers.[@R31] Recently, via unbiased genomic approaches, novel gene rearrangements have been described in PTC, such as the *PPL-NTRK1* (from periplakin, PPL)[@R32] and the *RBPMS-NTRK3* (from the RNA-binding protein with multiple splicing, RBPMS) gene fusion.[@R24]

*Human secretory breast carcinoma*: This is a rare but distinct subtype of infiltrating ductal carcinoma that was originally described in children and adolescents, but is now known to occur with equal incidence in adults. In 2002, Tognon *et al*[@R33] reported the *ETV6-NTRK3* gene fusion t(12;15)(p12;q26.1) as a pathognomonic genetic feature of this rare carcinoma.

*Glioblastoma*: Gene fusions occur in approximately 30--50% of patient with glioblastoma (GBM) samples and the Trk family could play a very important role. In 2013, Frattini *et al*[@R34] analysed 185 GBM samples and found two in-frame fusions involving *NTRK1* (*BCAN-NTRK1* and *NFASC-NTRK1*). In the same year, Shah *et al*[@R35] confirmed such genomic events as recurrent in a cohort of 24 GBM samples. In their work based on wide genomic screening of formalin-fixed paraffin-embedded (FFPE) specimens, Zheng *et al*[@R32] reported one in-frame fusion involving exon 21 of ARHGEF2 (encoding Rho/Rac guanine nucleotide exchange factor 2) and exon 10 of *NTRK1*, and two in-frame fusions involving exon 5 of *CHTOP* (encoding the chromatin target of PRMT1) and exon 10 of *NTRK1*, of the 115 brain tumour FFPE analyses. In 2014, Wu *et al*[@R36] applied a whole genome, whole exome and/or transcriptome sequencing to 127 samples of paediatric high-grade glioma (HGG), identifying recurrent fusions involving the neurotrophin receptor genes NTRK1, 2, or 3 in 40% of non-brainstem HGG.

*Miscellaneous tumours*: The recent efforts for identifying targetable genomic alterations through the use of next generation sequencing (NGS) are leading to the identification of novel and recurrent gene fusions in other various types of cancer. Ross *et al*[@R37] reported a NGS screening of 28 FFPE samples of intrahepatic cholangiocarcinoma, in which a novel gene fusion *RABGAP1L-NTRK1* was identified from a liver biopsy of a 62-year-old woman. Further, a recurrent gene fusion involving the ETV6 and the NTRK3 gene (ETV6-NTRK3) has been described in congenital fibrosarcoma.[@R38]

Trk inhibitors {#s1c}
==============

The growing number of identified gene fusions involving the NTRK gene enhanced the interest of the scientific community in the development of drugs with inhibitory capacity for the TK domain of Trk. Bertrand *et al*[@R39] published the high-resolution crystal structures of TrkA and TrkB in their apo-forms, as well as in complex with three nanomolar inhibitors. At least 40 residues of the kinase domain in its Asp-Phe-Gly (DFG)-in conformation, which potentially interact with a ligand in the ATP-binding site, are highly conserved between Trk proteins. Only 2 of the 40 residues are different between TrkA and TrkB, whereas the TrkB and TrkC ATP-binding sites are identical,[@R39] suggesting an easier design of pan-, rather than selective, inhibitors of the three distinct isoforms of Trk receptors. Even though this may be an issue in developing selective Trk agonists for the treatment of neurological diseases,[@R3] [@R40] it may be indeed advantageous for cancer treatment where inhibition of all three Trk members' gene fusions translates into wider antitumour activity.[@R41]

There is a limited number of reported Trk receptor tyrosine-kinase inhibitors in the literature and only a few of these have been tested in clinical trials ([table 1](#ESMOOPEN2015000023TB1){ref-type="table"}).

Entrectinib, formerly RXDX-101 and NMS-E628, is an orally bioavailable inhibitor of the TK TrkA, TrkB and TrkC, as well as of C-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK). Entrectinib can cross the blood--brain barrier, and could thus potentially be effective in the treatment of brain metastases and GBM by activating gene fusions of NTRK, ROS1 or ALK. Currently, two phase I trials are ongoing with this drug;[@R42] the RP2D of this drug is known and initial reports of substantial antitumour activity in cancers harbouring *NTRK1* gene fusions have been published.[@R19] [@R45] During screening for accrual in the European phase I trial of entrectinib (EudraCT Number: 2014-001326-15), the investigators identified a novel *LMNA--NTRK1* gene fusion in a patient with metastatic CRC who was enrolled in the trial. The patient achieved a meaningful response after only 1 month of treatment, suggesting for the first time that the *NTRK* gene may play a role as actionable oncogenic driver in this tumour type as well.[@R19] In February 2015, entrectinib was granted FDA Orphan Drug Designation for the treatment of TrkA, TrkB and TrkC positive non-small cell lung and colorectal tumours.[@R41]

LOXO-101 is a pan-Trk inhibitor with highly selective activity against the Trk kinase family. To date, in the phase I study, the maximum tolerated dose (MTD) has not yet been reached and pharmacokinetics show good systemic exposure of LOXO-101 after oral dosing, reaching approximately 98% inhibition of TrkA/B/C at peak concentrations with once daily dosing of 50 or 100 mg.[@R46] The clinical activity of this inhibitor was recently reported[@R47] in a case of a 41-year-old woman enrolled in the phase I trial who showed remarkable tumour response after treatment with LOXO-101.[@R47] The report by Doebele *et al*[@R47] also identified a *LMNA--NTRK1* gene fusion, previously unreported in sarcoma.

Altiratinib (DCC-2701)[@R48] and sitravatinib (MGCD516)[@R49] are multikinase inhibitors with reported in vitro activity against TrkA and TrkB, and were both recently tested in phase I clinical trials. Other multikinase inhibitors with claimed anti-Trk activity include TSR-011, PLX7486, DS-6051b, F17752 and cabozantinib (XL184), all in development in phase I/II trials ([table 2](#ESMOOPEN2015000023TB2){ref-type="table"}).

###### 

Ongoing phase I/II trials involving drugs with known inhibitory activity of NTRK-related kinases

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  NCT/EudraCT number   Title                                                                                                                                                                         Drug            Targets                        Phases          Patients   Start date
  -------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------- ------------------------------ --------------- ---------- ----------------
  NCT02219711          Phase 1/1b study of MGCD516 in patients with advanced cancer                                                                                                                  MGCD516         MET, AXL, c-kit, MER, DDR2,\   1               120        August 2014
                                                                                                                                                                                                                     VEGFR, PDGFR, RET, Trk, Eph                               

  NCT02568267          Basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors harboring NTRK1/2/3, ROS1, or ALK gene rearrangements (fusions)                        Entrectinib\    TrkA, TrkB, TrkC,\             2               300        October 2015
                                                                                                                                                                                                     (RXDX-101)      ROS1, ALK                                                 

  NCT02097810          Study of oral RXDX-101 in adult patients with locally advanced or metastatic cancer targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK molecular alterations                         1/2             175                            June 2014                  

  NCT02650401          Study of RXDX-101 in children with recurrent or refractory solid tumors and primary CNS tumors                                                                                1               80                             December 2015              

  NCT02048488/\        A phase I/IIa open-label, dose escalation and cohort expansion trial of oral TSR-011 in patients with advanced solid tumors and lymphomas                                     TSR-011         TrkA, ALK                      1/2             150        October 2012
  2013--000686--37                                                                                                                                                                                                                                                             

  NCT02637687          Oral TRK inhibitor LOXO-101 for treatment of advanced pediatric solid or primary central nervous system tumors                                                                LOXO-101        TrkA, TrkB, TrkC               1               36         December 2015

  NCT02122913          Oral TRK inhibitor LOXO-101 for treatment of advanced adult solid tumors                                                                                                      1               108                            April 2014                 

  NCT02576431          Study of LOXO-101 in subjects with NTRK fusion positive solid tumors                                                                                                          2               151                            October 2015               

  NCT01639508          Cabozantinib in patients with RET fusion-positive advanced non-small cell lung cancer and those with other genotypes: ROS1 or NTRK fusions or increased MET or AXL activity   Cabozantinib\   TrkA, RET, ROS1, MET, AXL      2               68         July 2012
                                                                                                                                                                                                     (XL184)                                                                   

  NCT01804530          Phase 1 study of PLX7486 as single agent and with gemcitabine plus nab-paclitaxel in patients with advanced solid tumors                                                      PLX7486         TrkA, TrkB, TrkC, FMS          1               160        August 2013

  NCT02279433          A first-in-human study to evaluate the safety, tolerability and pharmacokinetics of DS-6051b                                                                                  DS-6051b        TrkA,TrkB,TrkC, ROS1           1               70         September 2014

  2013--003009--24     Phase I-II study of F17752 in patients with advanced solid tumours                                                                                                            F17752          ALK, ROS1, Trk                 1/2             112        September 2015

  NCT02228811          A study of DCC-2701 in participants with advanced solid tumors                                                                                                                Altiratinib\    TrkA, TrkB, TrkC, MET,\        1               48         June 2014
                                                                                                                                                                                                     (DCC-2701)      TIE2, VEGFR                                               
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ALK, anaplastic lymphoma receptor tyrosine kinase; AXL, AXL receptor tyrosine kinase; c-kit, mast/stem cell growth factor receptor; CNS, central nervous system; DDR2, discoidin domain receptor 2; Eph, ephrin receptor tyrosine kinases; FMS, McDonough Feline Sarcoma Viral; MER, MER receptor tyrosine kinase; MET, hepatocyte growth factor receptor; PDGFR, platelet-derived growth factor receptor; RET, rearranged during transfection; ROS1, ROS proto-oncogene 1; TIE2, TEK receptor tyrosine kinase; TRK, tropomyosin-related kinases (also known as TrkA,B,C for kinase A, B and C); VEGFR, vascular endothelial growth factor receptor.

Acquired resistance to Trk inhibitors {#s1d}
=====================================

As with other targeted therapies, the onset of acquired (secondary) resistance may limit the efficacy of Trk inhibitors. Given their recent introduction into the therapeutic armamentarium of cancer treatment, very limited data are available regarding mechanisms underlying resistance. Recently, a study by Russo *et al* unveiled gene alterations associated with entrectinib-acquired resistance. In particular, it has been reported that entrectinib induced a remarkable clinical response in mCRC carrying a *LMNA-NTRK1* translocation, and tumour resistance developed after 4 months of response to discontinuous treatment (the cycle on which the patient was treated consisted of 4 days on, 3 days off, for 3 weeks, followed by a 1 week break in dosing), when the patient experienced progression of disease.[@R19] To characterise the molecular basis of acquired resistance to entrectinib, circulating tumour DNA (ctDNA) was collected longitudinally (liquid biopsies) during treatment in this individual case, and a tumour biopsy was obtained before entrectinib treatment and transplanted into immunodeficient mice in order to obtain a patient-derived xenograft (PDX), which was challenged with the same entrectinib regimen until resistance.[@R50] The study of ctDNA extracted from plasma samples collected before treatment initiation and at clinical relapse revealed two novel *NTRK1* genetic alterations, p.G595R and p.G667C, in the kinase domain of the protein, which were not detected in the ctDNA pretreatment but emerged in the circulation as early as 4 weeks from beginning of treatment. This finding was strengthened by the observation of the emergence of one of the same molecular alterations, the NTRK1 p.G695R, in the engrafted tumour biopsy expanded to multiple cohorts of mice treated with dosage and schedule of entrectinib matching those of the patient. The establishment of independent preclinical models with acquired resistance to entrectinib finally reinforced the conclusion that p.G595R or p.G667C *NTRK1* mutations are mechanisms of resistance to entrectinib. The authors also concluded that there is probably a dose-dependent effect affecting the emergence of each of the two mutations: *NTRK1* p.G667C emerged with exposure of low concentration of the inhibitor (absent with higher dose), and it is weaker than p.G595R in conferring resistance.[@R50] In the reported case,[@R19] indeed, the Trk pan-inhibitor entrectinib was administered with an intermittent dosing regimen that may have promoted or anticipated the development of resistance. Nevertheless, it is still unknown whether continuous or intermittent dosing will affect the emergence and/or the type of acquired mutations.

Conclusions and future perspectives {#s1e}
===================================

Gene fusions have been recognised as drivers in tumours for more than three decades, providing useful insights into carcinogenic processes. New deep-sequencing technologies are now illuminating a landscape of previously undetected gene fusions in a multitude of cancers.[@R51] In such an expanding scenario, *NTRK* gene fusions are emerging as novel targets across multiple tumour types, due to the growing availability of new drugs with anti-Trk activity.

Clearly, a major challenge in the development of these inhibitors is the low incidence in each single tumour histology that is counterbalanced by a wide distribution of Trk alterations across multiple histologies, thus increasing the number of patients who can be reached and treated with matched therapeutics in basket trials at the front edge of present clinical cancer research.[@R20] [@R52]
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